NEW YORK (GenomeWeb News) — Personalized medicine company Serametrix announced today a partnership with the Ludwig Institute for Cancer Research to develop serum-based diagnostics to predict and monitor treatment response in cancer patients.

As part of the agreement, LICR has licensed to Serametrix tumor antigen patents surrounding the use of the antigen NY-ESO-1 as a predictor of drug response.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.